Statistik Asas
| LEI | 549300S23HGL0P1Y1N41 |
| CIK | 1076682 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PolarityTE Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 18, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE THIRD RESTATED CERTIFICATE OF INCORPORATION OF POLARITYTE, INC. a Delaware corporation PolarityTE, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”) DOES HEREBY CERTIFY: ONE: The undersigned is the duly elected and acting Chief Executive Officer of the Company. TWO: This Certificate of A |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 REGENETP, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 18, 2023 |
AMENDMENT TO AMENDED AND RESTATED BYLAWS POLARITYTE, INC. a Delaware corporation Exhibit 3.2 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF POLARITYTE, INC. a Delaware corporation The undersigned, in his capacity as the duly appointed and incumbent Chief Executive Officer of PolarityTE, Inc. (the “Corporation”), hereby certifies on behalf of the Corporation that the following Amendment to the Amended and Restated Bylaws of the Corporation (the “Bylaws”) was duly adopted by the Bo |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form. |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-32404 PolarityTE, Inc. (Exact name of registrant as specified in its cha |
|
| August 1, 2023 |
AMENDMENT TO THE ASSET PURCHASE AGREEMENT Exhibit 2.2 AMENDMENT TO THE ASSET PURCHASE AGREEMENT This Amendment to the Asset Purchase Agreement (this “Amendment”) is entered into effective as of July 26, 2023 (the “Effective Date”), by and among Grander Acquisition LLC (“Purchaser”), PolarityTE, Inc., a Delaware corporation (“PTE”), PolartyTE MD, Inc., a Nevada corporation (“PTE MD”) and PolarityTE, Inc., a Nevada corporation (“PTE NV”, an |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 8, 2023 |
PolarityTE, Inc. 1960 S. 4250 West Salt Lake City, UT 84104 PolarityTE, Inc. 1960 S. 4250 West Salt Lake City, UT 84104 June 8, 2023 VIA EDGAR AND OVERNIGHT DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F St NE Washington, D.C. 20549 Attention: Joseph McCann Lauren Hamill Re: PolarityTE, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-267887 Initially Filed on October 14, 2022 Ladies and |
|
| June 7, 2023 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT by and among Grander Acquisition LLC, a Delaware limited liability company PolarityTE, inc., a Delaware corporation PolarityTE MD, Inc., a Nevada corporation and PolarityTE, Inc. a Nevada corporation June 6, 2023 TABLE OF CONTENTS ARTICLE I PURCHASE AND SALE 2 1.1 Acquired Assets 2 1.2 Excluded Assets 3 1.3 Assumed Liabilities 5 1.4 Excluded Liabilities 5 1.5 P |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File No. 001-32404 POLARITYTE, INC. (Exact |
|
| May 12, 2023 |
Amendment No. 2 Effective March 13, 2023, to Executive Employment Agreement with Cameron Hoyler Exhibit 10.1 EMPLOYMENT AGREEMENT AMENDMENT NO. 2 This Amendment No. 2 (the “Amendment”) to the Employment Agreement dated August 18, 2021, as amended by Amendment No. 1 thereto effective on August 15, 2022 (collectively the “Amended Agreement”), by and between Cameron J. Hoyler (the “Executive”) and PolarityTE, Inc., a Delaware corporation (“PTE”), and PolarityTE MD, Inc., a Nevada corporation (“ |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 27, 2023 |
Exhibit 21.1 List of Subsidiaries Name State of Formation PolarityTE, Inc. Nevada PolarityTE MD, Inc. Nevada Arches Research, Inc. Nevada Utah CRO Services, Inc. Nevada |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from Commission File No. 001-32404 POLARITYTE, INC. (Exact name of |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2023 |
PTE / Polarityte Inc / HONIG JONATHAN - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea173556-13ga1honigpolarity.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) POLARITYTE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 731094108 (CUSIP Number) December 31, 2022 (DATE OF EVENT WHICH REQUIRES |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 27, 2022 |
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company Exhibit 99.1 PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company SALT LAKE CITY, December 27, 2022 — PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials (the “Company”), today announced that it signed a non-binding letter of intent (the “LOI”) with Michael Brauser (“Brauser”) for him to make an offer to acqu |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
Exhibit 10.2 ADDENDUM TO PURCHASE AND SALE AGREEMENT THIS ADDENDUM (the ?Addendum?) to the Purchase and Sale Agreement dated October 25, 2021, as amended by Amendment No. 1 thereto dated March 15, 2022, (?Agreement?), between POLARITYTE, INC., a Delaware corporation (?Seller?), and BCG ACQUISITIONS LLC, a Utah limited liability company and/or assigns (?Buyer?) is made this 9th day of November 2022 |
|
| December 1, 2022 |
Lease Agreement between 1960 South 4250 West LLC and PolarityTE MD, Inc., dated December 1, 2022 Exhibit 10.1 LEASE AGREEMENT BETWEEN 1960 SOUTH 4250 WEST LLC, a Utah limited liability company, as LANDLORD AND POLARITYTE MD, INC., a Nevada corporation as TENANT DATED: November 30, 2022 1960 South 4250 West Salt Lake City, Utah BASIC LEASE INFORMATION Lease Date: November 30, 2022 Landlord: 1960 South 4250 West LLC, a Utah limited liability company Tenant: PolarityTE MD, Inc., a Nevada corpora |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File No. 001-32404 POLARITYTE, INC. (Ex |
|
| November 10, 2022 |
PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update SALT LAKE CITY, November 10, 2022 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial Updates |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2022 |
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company Exhibit 99.1 PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company SALT LAKE CITY, November 9, 2022 — PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael B |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 As filed with the Securities and Exchange Commission on October 14, 2022 Registration No. |
|
| October 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 PolarityTE, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| October 14, 2022 |
Form of Underwriting Agreement EX-1.2 2 ex1-2.htm Exhibit 1.2 UNDERWRITING AGREEMENT between PolarityTE, Inc. and A.G.P./ALLIANCE GLOBAL PARTNERS, as Representative of the Several Underwriters New York, New York October [●], 2022 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, New York 10022 As Representative of the several Underwriters named on Schedule 1 attached hereto Ladies and Gentlemen: The under |
|
| October 14, 2022 |
Form of H.C. Wainwright Warrant Exhibit 4.21 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 14, 2022 |
Exhibit 4.19 COMMON STOCK PURCHASE WARRANT POLARITYTE, INC. Warrant Shares: Initial Exercise Date: October [●], 2022 Issue Date: October [●], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| October 14, 2022 |
Exhibit 4.20 UNDERWRITER COMMON STOCK PURCHASE WARRANT POLARITYTE, INC. Warrant Shares: Initial Exercise Date: October [●], 2022 Issue Date: October [●], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| October 14, 2022 |
Exhibit 4.18 PRE-FUNDED COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Initial Exercise Date: October [●], 2022 Issue Date: October [●], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 12, 2022 |
PolarityTE – SkinTE® Investor Presentation – September 2022 Exhibit 99.1 |
|
| September 8, 2022 |
PolarityTE Announces Resignation of Jeff Dyer from its Board of Exhibit 99.1 PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors SALT LAKE CITY, September 8, 2022 ? PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. ?On behalf of our Board and PolarityTE?s management t |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| August 23, 2022 |
PTE / Polarityte Inc / HONIG JONATHAN - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) POLARITYTE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 731094108 (CUSIP Number) August 18, 2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursu |
|
| August 11, 2022 |
Exhibit 99.1 PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, August 11, 2022 ? PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for |
|
| August 11, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File No. 001-32404 POLARITYTE, INC. (Exact n |
|
| August 11, 2022 |
EXHIBIT 10.8 EMPLOYMENT AGREEMENT AMENDMENT NO. 1 This Amendment No. 1 (the ?Amendment?) to the Employment Agreement dated August 18, 2021 (the ?Original Agreement?), by and between Cameron J. Hoyler (the ?Executive?) and PolarityTE, Inc., a Delaware corporation (?PTE?), and PolarityTE MD, Inc., a Nevada corporation (?MD?) (PTE and MD are collectively referred to herein as the ?Company?) is made t |
|
| July 1, 2022 |
4,752,477 Shares of Common Stock Offered by the Selling Stockholder PolarityTE, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-265693 PROSPECTUS 4,752,477 Shares of Common Stock Offered by the Selling Stockholder PolarityTE, Inc. This prospectus relates to the offering and resale, from time to time, by the selling stockholder identified herein (the ?Selling Stockholder?) of up to 4,752,477 shares of common stock issued or issuable to the selling stockholder including ( |
|
| June 27, 2022 |
PolarityTE, Inc. 1960 S. 4250 West Salt Lake City, UT 84104 June 27, 2022 CORRESP 1 filename1.htm PolarityTE, Inc. 1960 S. 4250 West Salt Lake City, UT 84104 June 27, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: PolarityTE, Inc. – Registration Statement on Form S-1 (File No. 333-265693) Ladies and Gentlemen: In accordance with Rule 461 under the Sec |
|
| June 17, 2022 |
Calculation of Filing Fee Tables S-1 PolarityTE, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date |
|
| June 17, 2022 |
As filed with the Securities and Exchange Commission on June 17, 2022 Registration No. |
|
| June 17, 2022 |
Exhibit 21.1 List of Subsidiaries Name State of Formation PolarityTE, Inc. Nevada PolarityTE MD, Inc. Nevada Arches Research, Inc. Nevada Utah CRO Services, Inc. Nevada |
|
| June 16, 2022 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 01:05 PM 06/15/2022 FILED 01:05 PM 06/15/2022 SR 20222732186 - File Number 2894506 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTBILE PREFERRED STOCK AND SERIES B CONVERTBILE PREFERRED STOCK OF POLARITYTE, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) PolarityTE, Inc., a |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 8, 2022 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Initial Exercise Date: June 8, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| June 8, 2022 |
EX-10.1 7 ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 5, 2022, between PolarityTE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| June 8, 2022 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 8, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 5, 2022, between PolarityTE, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agreeme |
|
| June 8, 2022 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 8, 2022 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 8, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 5, 2022, between PolarityTE, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set fort |
|
| June 7, 2022 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-262671 PROSPECTUS SUPPLEMENT (To Prospectus dated April 7, 2022) PolarityTE, Inc. 445,500 Shares of Common Stock Pre-Funded Warrants to Purchase 1,138,659 Shares of Common Stock 1,138,659 Shares of Common Stock Underlying the Pre-Funded Warrants Pursuant to this prospectus supplement and the accompanying prospectus, we are offering to |
|
| June 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 6, 2022 |
Exhibit 99.1 PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules SALT LAKE CITY, June 6, 2022 ? PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 19, 2022 |
PolarityTE Investor Presentation – May 2022 EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| May 16, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE (Third) RESTATED CERTIFICATE OF INCORPORATION OF POLARITYTE, INC. PolarityTE, Inc. (the ?Corporation?), a corporation duly organized and existing under the laws of the State of Delaware, by its duly authorized officer, does hereby certify that: 1. The Board of Directors of the Corporation has duly adopted resolutions (i) authorizing the Corporation to ex |
|
| May 16, 2022 |
PolarityTE to Effectuate 1-for-25 Reverse Stock Split EX-99.1 3 ex99-1.htm Exhibit 99.1 PolarityTE to Effectuate 1-for-25 Reverse Stock Split SALT LAKE CITY, May 16, 2022 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effectuate a 1-for-25 reverse stock split of the Company’s issued and outstanding common stock, which will be effective under Dela |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from to Commission File No. 001-32404 POLARITYTE, INC. (Exact |
|
| May 16, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY, May 16, 2022 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financi |
|
| May 16, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 13, 2022 |
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE® Exhibit 99.1 PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE? SALT LAKE CITY, May 13, 2022 ? PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company?s open IND. Established under the 21st Century Cures Act, RMAT design |
|
| May 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 3, 2022 |
Exhibit 99.1 PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers SALT LAKE CITY, May 3, 2022 – PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), |
|
| May 3, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 2, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 2, 2022 |
Exhibit 10.3 Promissory Note $400,000.00 Salt Lake City, Utah FOR VALUE RECEIVED, the undersigned, JP Lawrence Biomedical, Inc., a Delaware corporation with its principal offices at 1072 West RSI Drive, Logan, Utah 84321, (the ?Payor?) hereby promises to pay to the order of Utah CRO Services, Inc., a Nevada corporation with its principal offices at 1960 South 4250 West, Salt Lake City, Utah 84104, |
|
| April 18, 2022 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 REAL ESTATE PURCHASE AND SALE AGREEMENT THIS REAL ESTATE PURCHASE AND SALE AGREEMENT (“Agreement”), is entered into and shall be effective as of the 14th day of April, 2022, by and between IBEX PROPERTY LLC, a Nevada limited liability company (“Seller”), and JP Lawrence Land and Building LLC, a Utah limited liability company (“Purchaser”). Seller and Purchaser are |
|
| April 18, 2022 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is entered into on April 14, 2022, by and among JP Lawrence Biomedical, Inc., a Delaware corporation (“Buyer”), and Utah CRO Services, Inc., a Nevada corporation (“Seller”). Buyer and Seller are referred to collectively herein as the “Parties.” Seller owns all of the outstanding capital stoc |
|
| April 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 4, 2022 |
PolarityTE, Inc. 1960 S. 4250 West Salt Lake City, Utah 84104 April 4, 2022 PolarityTE, Inc. 1960 S. 4250 West Salt Lake City, Utah 84104 April 4, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Davis, Celeste Murphy RE: PolarityTE, Inc. Registration Statement on Form S-3 Originally Filed February 11, 2022 File No.: 333-262671 Pursuant to Rule 461 promulgated under the Securitie |
|
| March 30, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from Commission File No. 001-32404 POLARITYTE, INC. (Exact name of |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY, March 30, 2022 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported finan |
|
| March 30, 2022 |
Exhibit 107 S-3 PolarityTE, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Paid In Conne |
|
| March 25, 2022 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 17, 2022 |
EX-4.2 5 ex4-2.htm Exhibit 4.2 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT polarityte, inc. wARRANT SHaRES: iNITIAL EXERCISE DATE:september , 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| March 17, 2022 |
PolarityTE, Inc. Warrants to purchase up to 9,090,910 Shares of Common Stock 424B3 1 form424b3.htm Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated January 11, 2021) PolarityTE, Inc. Warrants to purchase up to 9,090,910 Shares of Common Stock This prospectus supplement (“Supplement”) modifies, supersedes, and supplements certain information contained in, and should be read in conjunction with, the |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 17, 2022 |
PolarityTE Announces $5.0 Million Registered Direct Offering EX-99.1 9 ex99-1.htm Exhibit 99.1 PolarityTE Announces $5.0 Million Registered Direct Offering SALT LAKE CITY, March 16, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) (“PolarityTE” or the “Company”), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institu |
|
| March 17, 2022 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT polarityte, inc. wARRANT SHaRES: iNITIAL EXERCISE DATE:september , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September , 2022 (the ?Initial E |
|
| March 17, 2022 |
PolarityTE Announces Closing of $5.0 Million Registered Direct Offering EX-99.2 13 ex99-2.htm Exhibit 99.2 PolarityTE Announces Closing of $5.0 Million Registered Direct Offering SALT LAKE CITY, March 16, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) (“PolarityTE” or the “Company”), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has closed its previously announced registered direct offering with a single |
|
| March 17, 2022 |
Exhibit 3.2 polarityte, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE 151 GENERAL CORPORATION LAW The undersigned, Richard Hague and Cameron J. Hoyler, do hereby certify that: 1. They are the President and Secretary, respectively, of PolarityTE, Inc., a Delaware corporation (the ?Corporation?). 2. The C |
|
| March 17, 2022 |
Exhibit 3.1 polarityte, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE 151 GENERAL CORPORATION LAW The undersigned, Richard Hague and Cameron J. Hoyler, do hereby certify that: 1. They are the President and Secretary, respectively, of PolarityTE, Inc., a Delaware corporation (the ?Corporation?). 2. The C |
|
| March 17, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 15, 2022, between PolarityTE, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set f |
|
| March 17, 2022 |
PolarityTE, Inc. Warrants to purchase up to 8,016,033 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated January 22, 2021) PolarityTE, Inc. Warrants to purchase up to 8,016,033 Shares of Common Stock This prospectus supplement (?Supplement?) modifies, supersedes, and supplements certain information contained in, and should be read in conjunction with, the prospectus supplement |
|
| March 17, 2022 |
Exhibit 10.2 15 March 2022 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering (the ?Offering?) by PolarityTE, Inc. (the ?Company?) of (i) shares of its preferred stock, par value $0.001 per share, and (ii) warrants to purchase shares of the Company?s common stock, $0.001 par value per share (the ?Common Stock?). This letter confirms that, in consideration for |
|
| March 16, 2022 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus dated February 22, 2019) PolarityTE, Inc. 3,000.000435 Shares of Series A Convertible Preferred Stock 2,000.00029 Shares of Series B Convertible Preferred Stock (and 16,393,445 Shares of Common Stock issuable upon the conversion of such Preferred Stock) Warrants to Purchase up to 16,393,445 |
|
| March 15, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 15, 2022 |
Exhibit 10.2 PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (?Agreement?) made this 14th day of March, 2022 (the ?Effective Date?), by and between ADCOMP LLC, a Utah limited liability company (?Seller?), and POLARITYTE, INC., a Delaware corporation (?Buyer?). RECITALS: WHEREAS, Buyer is the tenant under a lease dated December 12, 2017 (the ?Lease?) with Seller for the Premises (as de |
|
| March 15, 2022 |
EX-10.4 3 ex10-4.htm Exhibit 10.4 AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT THIS AMENDMENT NO. 1 (the “Amendment”) to the Purchase and Sale Agreement dated October 25, 2021 (“Agreement”), between POLARITYTE, INC., a Delaware corporation (“Seller”), and BCG ACQUISITIONS LLC, a Utah limited liability company and/or assigns (“Buyer”) is made this 15th day of March 2022. Capitalized terms used in |
|
| March 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| March 11, 2022 |
PolarityTE Investor Presentation – March 2022 EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| March 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 10, 2022 |
PolarityTE Investor Presentation – March 2022 Exhibit 99.1 |
|
| March 4, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 22, 2022 |
Exhibit 99.1 SkinTE? Met Primary and Secondary Endpoints in Multicenter, Randomized Controlled Trial in Venous Leg Ulcers SALT LAKE CITY, February 22, 2022 ? PolarityTE, Inc. (Nasdaq: PTE) today announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers (VLU) with its investigational product SkinTE? plus standard of care (SOC) vs SOC alone (NCT03881 |
|
| February 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| February 17, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| February 17, 2022 |
PolarityTE Announces Allowance of Fourth U.S. Patent Exhibit 99.1 PolarityTE Announces Allowance of Fourth U.S. Patent SALT LAKE CITY, February 17, 2022?PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S. Application No. 17/326,734 filed on May 21, 2021. This is the Company?s fourth |
|
| February 11, 2022 |
EX-4.3 2 ex4-3.htm Exhibit 4.3 POLARITYTE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a |
|
| February 11, 2022 |
Form of Subordinated Indenture EX-4.4 3 ex4-4.htm Exhibit 4.4 POLARITYTE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). |
|
| February 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-3 PolarityTE, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effect |
|
| February 11, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| February 11, 2022 |
As filed with the Securities and Exchange Commission on February 11, 2022 Registration No. |
|
| January 18, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication SALT LAKE CITY, Jan. 18, 2022 – PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investiga |
|
| January 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 3, 2022 |
S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on January 3, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POLARITYTE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1529524 (State or Other Jurisdiction of (I.R.S. Employer Incorporat |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 20, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Announces Submission of Complete Response to FDA’s Clinical Hold Correspondence for SkinTE® Investigational New Drug Application SALT LAKE CITY, December 20, 2021 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food |
|
| December 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 17, 2021 |
EX-10.2 2 ex10-2.htm Exhibit 10.2 PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (“Agreement”), made this 25th day of October, 2021 (the “Effective Date”), by and between POLARITYTE, INC., a Delaware corporation (“Seller”), and BCG ACQUISITIONS LLC, a Utah limited liability company and/or assigns (“Buyer”). RECITALS: WHEREAS, Seller is the tenant under a lease and has a binding legal |
|
| December 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2021 |
Exhibit 99.1 PolarityTE Reports Third Quarter Financial Results and Provides Business Update PolarityTE to host conference call and webcast today, November 10, 2021, at 8:30 a.m. ET SALT LAKE CITY, November 10, 2021 ? PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for t |
|
| November 10, 2021 |
Exhibit 10.4 CONSULTING AGREEMENT This CONSULTING AGREEMENT (the ?Agreement?) is made and effective as of the 1st day of September 2021, by and between David Seaburg, an individual (?Consultant?), and PolarityTE, Inc., a Delaware corporation (?PTE?), and PolarityTE MD, Inc., a Nevada corporation (?MD?) (PTE and MD are collectively referred to herein as the ?Company?). WHEREAS, the Company desires |
|
| November 10, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission File No. 001-32404 POLARITYTE, INC. (Exact name of registrant as specified in its charter) delaware 06-1529524 (State or Other Jurisdiction of (I.R.S. Employer Incorpo |
|
| October 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 7, 2021 |
PolarityTE Provides Update on Investigational New Drug Application EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Provides Update on Investigational New Drug Application SALT LAKE CITY, October 7, 2021 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers su |
|
| October 1, 2021 |
EX-3.1 2 ex3-1.htm Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 03:35 PM 09/2812021 FILED 03:35 PM 09/2812021 SR 20213366152 - FileNumber 2894506 (Third) RESTATED CERTIFICATE OF INCORPORATION OF POLARITYTE, INC. (PolarityTE, Inc., was originally incorporated under the name of SMD Group, Inc., by filing with the Secretary of State of Delaware, a certificate of |
|
| October 1, 2021 |
Exhibit 3.2 POLARITYTE, INC. AMENDED AND RESTATED BYLAWS (As of September 28, 2021) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Boar |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| September 9, 2021 |
PolarityTE Investor Presentation – September 2021 EX-99.1 2 ex99-1.htm Exhibit 99-1 |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 2, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair of Strategic Review Committee Ryan Mathis, MD, named Chief Medical Officer SALT LAKE CITY, September 2, 2021 – PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 24, 2021 |
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE® Exhibit 99.1 PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE? SALT LAKE CITY, August 24, 2021 ? PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application ( |
|
| August 24, 2021 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into as of August 18, 2021, by and between Cameron J. Hoyler (the “Executive”) and PolarityTE, Inc., a Delaware corporation (“PTE”), and PolarityTE MD, Inc., a Nevada corporation (“MD”) (PTE and MD are collectively referred to herein as the “Company”). WHEREAS, the Company desires |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 24, 2021 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into as of August 18, 2021, by and between Richard Hague (the “Executive”) and PolarityTE, Inc., a Delaware corporation (“PTE”), and PolarityTE MD, Inc., a Nevada corporation (“MD”) (PTE and MD are collectively referred to herein as the “Company”). WHEREAS, the Company desires to |
|
| August 24, 2021 |
EX-10.3 4 ex10-3.htm Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into as of August 18, 2021, by and between Jacob Patterson (the “Executive”) and PolarityTE, Inc., a Delaware corporation (“PTE”), and PolarityTE MD, Inc., a Nevada corporation (“MD”) (PTE and MD are collectively referred to herein as the “Company”). WHEREAS, the Company desires t |
|
| August 16, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 12, 2021 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 PolarityTE Reports Second Quarter Financial Results and Provides Business Update PolarityTE to host conference call and webcast today, August 12, 2021, at 4:30 p.m. ET SALT LAKE CITY, August 12, 2021 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported finan |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Commission File No. 001-32404 POLARITYTE, INC. (Exact name of registrant as specified in its charter) delaware 06-1529524 (State or Other Jurisdiction of (I.R.S. Employer Incorporatio |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 12, 2021 |
Certificate of Elimination for Series A Junior Participating Preferred Stock EX-3.1 2 ex3-1.htm Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF POLARITYTE, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) PolarityTE, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: that the Certificate of Designation |
|
| July 28, 2021 |
PolarityTE Investor Presentation – July 2021 EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| July 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 28, 2021 |
EX-99.2 3 ex99-2.htm Exhibit 99.2 SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial Data Included in Investigational New Drug Application Submitted on July 23, 2021 Company Announces Completion of Study Evaluating SkinTE for the treatment of Venous Leg Ulcers SALT LAKE CITY, July 28, 2021 – PolarityTE, Inc. (Nasdaq: PTE) today announced final data from a |
|
| July 26, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 26, 2021 |
PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers Exhibit 99.1 PolarityTE Submits Investigational New Drug Application for SkinTE? in Chronic Cutaneous Ulcers SALT LAKE CITY, July 26, 2021 ? PolarityTE, Inc. (Nasdaq: PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to evaluate its SkinTE product for the pr |
|
| July 12, 2021 |
Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 12, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Receives Notice of Allowance for Chinese Patent PolarityTE’s Worldwide Patent Portfolio Grows to 12 Allowed or Granted Patents SALT LAKE CITY, July 12, 2021 — PolarityTE, Inc. (Nasdaq: PTE) today announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 2015800753 |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Commission File No. 001-32404 POLARITYTE, INC. (Exact name of registrant as specified in its charter) delaware 06-1529524 (State or Other Jurisdiction of (I.R.S. Employer Incorporation |
|
| May 13, 2021 |
Presentation Slides dated May 13, 2021, of PolarityTE, Inc EX-99.2 3 ex99-2.htm Exhibit 99.2 |
|
| May 13, 2021 |
Exhibit 99.1 PolarityTE Reports First Quarter Results and Provides Business Update First Quarter 2021 Total Revenues of $4.71 million Compared to $3.59 million in Fourth Quarter of 2020 PolarityTE to host conference call and webcast today, May 13, 2021 at 4:30 p.m. ET SALT LAKE CITY, May 13, 2021 ? PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and |
|
| May 13, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint Reports Peer-Reviewed Publication of Interim Results from Diabetic Foot Ulcer Trial in International Wound Journal SALT LAKE CITY, May 10, 2021 – PolarityTE, Inc. (Nasdaq: PTE) today announced preliminary topline data demonstrating that a multi-center randomized controlled trial eval |
|
| May 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2021 |
EX-99.2 3 ex99-2.htm Exhibit 99.2 |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 30, 2021 |
As filed with the Securities and Exchange Commission on March 30, 2021 Registration No. |
|
| March 30, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 30, 2021 |
EX-1.1 2 ex1-1.htm Exhibit 1.1 Execution Version PolarityTE, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement March 30, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: PolarityTE, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent” |
|
| March 30, 2021 |
EX-4.13 3 ex4-13.htm Exhibit 4.13 Description of Capital Stock The following description of our common stock and preferred stock, together with the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subj |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from Commission File No. 000-51128 POLARITYTE, INC. (Exact name of |
|
| March 30, 2021 |
Presentation Slides dated March 30, 2021, of PolarityTE, Inc. EX-99.2 3 ex99-2.htm Exhibit 99.2 |
|
| March 30, 2021 |
PolarityTE, Inc. Up to $50,000,000 of Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus dated February 22, 2019) PolarityTE, Inc. Up to $50,000,000 of Shares of Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “sales agreement”) with Cantor Fitzgerald & Co. (“Cantor”) relating to shares of our common stock offered by this prospectus suppleme |
|
| March 30, 2021 |
Change in Control Compensation Plan EX-10.8 5 ex10-8.htm Exhibit 10.8 POLARITYTE, INC. CHANGE IN CONTROL COMPENSATION PLAN ARTICLE I - INTRODUCTION Section 1.1 Background. The Board of Directors of PolarityTE, Inc. (the “Company”), has considered the effect a Change in Control of the Company may have on certain Executives of the Company. The Board has determined that it is in the best interests of the Company and its shareholders to |
|
| March 30, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results Fourth Quarter Revenues of $3.59 million and Full Year 2020 Revenues of $10.13 million PolarityTE to host conference call and webcast today, March 30, 2021 at 8:00 a.m. ET SALT LAKE CITY, March 30, 2021 – PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products an |
|
| March 9, 2021 |
Corporate information slide deck dated March 2021 of PolarityTE, Inc. EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| March 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* POLARITYTE, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of |
|
| February 11, 2021 |
AGREEMENT TO FILE JOINT SCHEDULE 13G Exhibit 99.1 AGREEMENT TO FILE JOINT SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of PolarityTE, Inc., a Delaware corporation. The |
|
| February 10, 2021 |
PolarityTE Provides Corporate Update EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Provides Corporate Update SALT LAKE CITY, February 10, 2021 — PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareholder value by pursuing pre-market approval for SkinTE® from the U.S. Food and Drug Administr |
|
| February 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| February 3, 2021 |
Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| February 3, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Receives Allowance for Additional U.S. Patent PolarityTE’s U.S. Patent Portfolio is Growing with Allowance of U.S. Patent Application No. 16/165,169 SALT LAKE CITY, February 3, 2021 — PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/165,169 filed |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 26, 2021 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: 8,016,033 Issue Date: January , 2021 Initial Exercise Date: January , 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| January 26, 2021 |
Exhibit 10.1 POLARITYTE, INC. January 22, 2021 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: PolarityTE, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all or part of the Common Stock Purchase Warrants of the Company (the “Existing Warrants”) currently held by you (the “Holder”). The Existing Warran |
|
| January 26, 2021 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus dated February 22, 2019) PolarityTE, Inc. Common Stock Purchase Warrants to Purchase up to 8,016,033 Shares of Common Stock Placement Agent Warrants to Purchase up to 480,962 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering common |
|
| January 26, 2021 |
EX-4.2 3 ex4-2.htm Exhibit 4.2 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: January , 2021 Initial Exercise Date: January , 2021 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he |
|
| January 26, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 22, 2021 |
PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million Exhibit 99.1 PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million SALT LAKE CITY, UT, January 22, 2021 – PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the agreement by an accredited investor to exercise certain |
|
| January 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 21, 2021 |
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial Company Expects to Release Topline Data at the Symposium on Advanced Wound Care—Spring 2021 SALT LAKE CITY, January 21, 2021 – PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enr |
|
| January 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 14, 2021 |
EX-99.1 7 ex99-1.htm Exhibit 99.1 PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SALT LAKE CITY, January 14, 2021 — PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today the closing of |
|
| January 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 14, 2021 |
EX-4.3 4 ex4-3.htm Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: January , 2021 Initial Exercise Date: January , 2021 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions he |
|
| January 14, 2021 |
EX-4.2 3 ex4-2.htm Exhibit 4.2 SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: January , 2021 Initial Exercise Date: January , 2021 THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi |
|
| January 14, 2021 |
Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: January , 2021 Initial Exercise January , 2021 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| January 14, 2021 |
EX-10.1 6 ex10-1.htm Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 11, 2021, between PolarityTE, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto, including its successors and assigns (the “Purchaser”) WHEREAS, subject to the terms and conditions set forth in this Agreem |
|
| January 13, 2021 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus dated February 22, 2019) PolarityTE, Inc. 6,670,000 Shares of Common Stock Pre-Funded Warrants to Purchase 2,420,910 Shares of Common Stock Warrants to Purchase up to 9,090,910 Shares of Common Stock Placement Agent Warrants to Purchase up to 545,455 Shares of Common Stock Pursuant to this p |
|
| January 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 12, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SALT LAKE CITY, January 12, 2021 — PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into |
|
| January 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* PolarityTE, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 731094108 (CUSIP Number) Liad Me |
|
| January 11, 2021 |
Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| January 11, 2021 |
PolarityTE Announces Formation of Strategic Review Committee Exhibit 99.1 PolarityTE Announces Formation of Strategic Review Committee SALT LAKE CITY, January 11, 2021 – PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value. The committee will focus on reviewing operational |
|
| December 30, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* PolarityTE, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 731094108 (CUSIP Number) Liad Me |
|
| December 29, 2020 |
Exhibit 99.1 POLARITYTE, INC. 2020 STOCK OPTION AND INCENTIVE PLAN (As Amended November 19, 2020) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the PolarityTE, Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of PolarityTE, Inc. (the “Company”) and |
|
| December 29, 2020 |
As filed with the Securities and Exchange Commission on December 29, 2020 Registration No. |
|
| December 23, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 21, 2020, between PolarityTE, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto, including its successors and assigns (the “Purchaser”) WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to |
|
| December 23, 2020 |
Exhibit 4.2 SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: December 23, 2020 Initial Exercise Date: December 23, 2020ra THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herei |
|
| December 23, 2020 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus dated February 22, 2019) PolarityTE, Inc. 5,450,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,238,043 Shares of Common Stock Warrants to Purchase up to 10,688,043 Shares of Common Stock Placement Agent Warrants to Purchase up to 641,283 Shares of Common Stock Pursuant to this |
|
| December 23, 2020 |
Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: December 23, 2020 Initial Exercise Date: December 23, 2020 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| December 23, 2020 |
Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT polarityte, inc. Warrant Shares: Issue Date: December 23, 2020 Initial Exercise Date: December 23, 2020 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| December 23, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 22, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| December 22, 2020 |
PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SALT LAKE CITY, December 22, 2020 — PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 30, 2020 |
Exhibit 99.1 PolarityTE Receives Allowance for First U.S. Patent Allowance of U.S. Patent Application No. 14/954,335 Further Bolsters PolarityTE’s Patent Portfolio SALT LAKE CITY, November 30, 2020 — PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. This is the Company’s first patent allowa |
|
| November 30, 2020 |
Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 23, 2020 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229584 PROSPECTUS SUPPLEMENT (To Prospectus dated February 22, 2019 and Prospectus Supplement dated February 12, 2020) PolarityTE, Inc. 10,638,298 Shares of Common Stock Warrants to Purchase 10,638,298 Shares of Common Stock This prospectus supplement updates and supplements the prospectus supplement dated February 12, 2020 to the ori |
|
| November 23, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 November , 2020 Holders of Warrants Issued on February 14, 2020 Re: Reprice of Common Stock Warrants To Whom It May Concern: PolarityTE, Inc. (the “Company”) is pleased to notify you that, subject to the terms of his letter agreement, the Company is reducing the exercise price of all of the Common Stock Warrants (“Warrants”) issued to you (the “Holder”) on Februar |
|
| November 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2020 |
Presentation Slides dated November 9, 2020, of PolarityTE, Inc. Exhibit 99.2 |
|
| November 9, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2020 |
Exhibit 99.1 PolarityTE Reports Third Quarter 2020 Results SALT LAKE CITY, November 9, 2020 – PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE will host a conference call and webcast today, November 9, 2020 at 8:00 a.m. ET. Highlights ● Total revenues |
|
| November 9, 2020 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 Service pricing information in Section 3 of this agreement has been redacted based on the registrant’s determination the information is not material and would likely cause competitive harm. COVID-19 LABORATORY SERVICES AGREEMENT This Covid-19 Laboratory Services Agreement (“Agreement”) is made between Co-Diagnostics, Inc., a Utah corporation having its principal p |
|
| November 9, 2020 |
Exhibit 10.2 Pricing information in Exhibit B to this agreement has been redacted based on the registrant’s determination the information is not material and would likely cause competitive harm. Rental Agreement for LGC Genomics Oktopure Extraction Machine Agreement made on this 2nd day of September, 2020, between Co-Diagnostics, Inc., a Utah corporation (herein after called “CoDx”) with offices a |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Commission File No. 001-32404 POLARITYTE, INC. (Exact name of registrant as specified in its charter) delaware 06-1529524 (State or Other Jurisdiction of (I.R.S. Employer Incorpora |
|
| November 2, 2020 |
Exhibit 99.1 PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE® PolarityTE Plans to Submit an Investigational New Drug (IND) Submission for One or More Indications in the Second Half of 2021 SALT LAKE CITY, November 2, 2020 — PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA follow |
|
| November 2, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission File |
|
| October 7, 2020 |
POLARITYTE, INC. 2019 ANNUAL REPORT TABLE OF CONTENTS Section Page No. Our Company 1 Market for Common Equity and Related Stockholder Matters 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 3 Financial Statements 12 As used in this report, the terms “we”, “us”, “our”, “the Company”, and “PolarityTE” mean PolarityTE, Inc., a Delaware corporation, and our whol |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| September 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 06-1529524 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 123 Wr |
|
| September 29, 2020 |
PolarityTE Announces Termination of Shareholder Rights Plan EX-99.1 7 ex99-1.htm Exhibit 99.1 PolarityTE Announces Termination of Shareholder Rights Plan SALT LAKE CITY, September 29, 2020 – PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives. The termination of the shareholder righ |
|
| September 29, 2020 |
EX-4.1 6 ex4-1.htm Exhibit 4.1 FIRST AMENDMENT TO RIGHTS AGREEMENT This FIRST AMENDMENT TO RIGHTS AGREEMENT, dated as of September 28, 2020 (this “Amendment”), by and between PolarityTE, Inc., a Delaware corporation (the “Company”), and Equity Stock Transfer, LLC, as rights agent (the “Rights Agent”). All capitalized terms used herein and not otherwise defined herein shall have the meaning(s) ascr |
|
| September 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 POLARITYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-32404 06-1529524 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 23, 2020 |
PolarityTE Corporate Presentation September 2020 Exhibit 99.1 |
